Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
PMV Pharmaceuticals, Inc
Eli Lilly and Company
Terremoto Biosciences Inc.
Takeda
Kidney Cancer Research Bureau
Second Life Therapeutics
Eli Lilly and Company
Tanabe Pharma America, Inc.
Eli Lilly and Company
LigaChem Biosciences, Inc.
Bolt Biotherapeutics, Inc.
Palleon Pharmaceuticals, Inc.
ModeX Therapeutics, An OPKO Health Company
Klus Pharma Inc.
DualityBio Inc.
Intensity Therapeutics, Inc.
RAPT Therapeutics, Inc.
UNICANCER
Cyteir Therapeutics, Inc.
Aminex Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
NantCell, Inc.
Second Affiliated Hospital of Guangzhou Medical University
GeneMedicine Co., Ltd.
NextCure, Inc.
Icahn School of Medicine at Mount Sinai
CytomX Therapeutics
Fusion Pharmaceuticals Inc.
Klus Pharma Inc.
Kineta Inc.
Ludwig Institute for Cancer Research
ImmVira Pharma Co. Ltd
Silverback Therapeutics
NKGen Biotech, Inc.
Petra Pharma
Stanford University
Millennium Pharmaceuticals, Inc.
Memorial Sloan Kettering Cancer Center
Otsuka Novel Products GmbH
Memorial Sloan Kettering Cancer Center
University of Plymouth